HOME >> MEDICINE >> NEWS
Investigational drug may protect cancer and AIDS patients from side effects of pain relief therapy

A drug developed to relieve one of the major side effects of pain therapy for cancer patients may offer an added benefit for AIDS patients, researchers from the University of Chicago and the Children's Hospital of Philadelphia reported Saturday, October 11, at the 2003 Annual Meeting of the American Society of Anesthesiologists in San Francisco.

Methylnaltrexone (MNTX) was invented to reverse the constipation caused by powerful opioid-based pain relievers such as morphine, OxyContin or Percocet taken by patients with cancer or AIDS. Opiates also appear to increase the ability of HIV to infect certain immune system cells.

This laboratory study found that MNTX blocked increases in HIV entry and replication that occur when immune cells are exposed to therapeutic doses of morphine. In this in-vitro study, very small amounts of methylnaltrexone blocked this process.

"If our studies are borne out in future clinical trials, methylnaltrexone may improve the care of patients who take opioids for pain caused by AIDS," said Jonathan Moss, M.D., Ph.D., professor of anesthesia and critical care at the University of Chicago and director of the study.

Many AIDS patients and more than 500,000 patients with advanced cancer depend on drugs like morphine for pain relief. One side effect of these pain relievers is severe constipation, which can be so distressing that many patients discontinue their pain medication.

Methylnaltrexone was invented to solve this problem by the late Leon Goldberg, a University of Chicago pharmacologist. To help a dying friend with morphine-induced constipation, Goldberg took naltrexone, an established drug that blocks the effects of morphine, and altered it slightly so that it could no longer cross the protective barrier that surrounds the brain.

Consequently, it did not interfere with morphine's effect on pain, which is centered in the brain, but it did block morphine's effects on gut motility, which a
'"/>

Contact: John Easton
jeaston@uchospitals.edu
773-702-6241
University of Chicago Medical Center
14-Oct-2003


Page: 1 2

Related medicine news :

1. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
2. Investigational drug may provide new option for preventing transplant organ rejection
3. Investigational drug brings new hope to kidney cancer patients
4. Investigational mesh jackets studied as an experimental therapy for heart failure
5. Investigational oral contraceptive reduces premenstrual and menstrual symptoms
6. Investigational drug study may determine if lung cancer is preventable in cigarette smokers
7. New study in Nature demonstrates protection against cell death during heart attack
8. Simple intervention encourages sun protection behaviors
9. Red wine protects the heart
10. Sunflower seed oil can protect low birth weight babies from infection
11. Physical activity linked to protection from Parkinsons disease

Post Your Comments:
(Date:7/29/2015)... ... July 29, 2015 , ... The healthcare analytics market is ... region. Factors such as the rising pressure to curb healthcare costs, big data ... venture capital investments are driving market growth. Check 149 data tables & 57 ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to The Spirits Business on ... directly responsible for stimulating and perpetuating alcohol use disorders. Humans have the same gene, ... the National academy of Sciences, and has given researchers inklings to explore Rsu1 in ...
(Date:7/29/2015)... ... 2015 , ... According to the Miami Herald on July 18th ... health disorders. Acu-detox may begin taking off in the South Florida community as more ... Although acupuncture is not a new practice, it is not widely used, but has ...
(Date:7/29/2015)... ... 29, 2015 , ... San Fernando Valley skin doctor , Dr. Peyman ... only, patients can get the complete treatment process with a 10 percent discount on ... treatment and have loose or sagging skin. , As the only non-surgical procedure ...
(Date:7/29/2015)... ... July 29, 2015 , ... Today marks a significant achievement in bringing ... growth companies and is led by a group of experienced investors, has tapped into ... with their dollars to be a part of the fund. The Sofia Fund ...
Breaking Medicine News(10 mins):Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Sofia Fund Surpasses Investor Goals 2
(Date:7/29/2015)... BOCA RATON, Fla. , July 29, 2015 ... immediate launch of Azelastine HCl Nasal Solution, 0.1%. The ... this Abbreviated New Drug Application (ANDA), which is ... Meda Pharmaceuticals. Azelastine hydrochloride nasal solution (nasal spray) ... on June 2015 IMS Health sales data.  Azelastine ...
(Date:7/29/2015)... , July 29, 2015 ... research report "Global Industry Insight: Microfluidic Devices ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles. ... Microfluidic devices  ...
(Date:7/29/2015)... , July 29, 2015 Commenting ... transaction closed, CFO Simon Dingemans reveals sales ... are performing in line with expectations. Ahead of a ... to sustainable innovation. The interview and transcript ... MerchantCantos produces in-depth interviews, documentaries and webcasts with senior ...
Breaking Medicine Technology:Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 2Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 3Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 4Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 5
Cached News: